Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia Clinical-stage biotech granted orphan drug designation for the treatment of CAH, a rare endocrine disease San Francisco – December 4, 2017 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced that the U.S. Food […]
ST. LOUIS, MO (Oct. 25, 2017)—RiverVest Venture Partners announced today that Ronald T. Borchardt, Ph.D. and Jared Rutter, Ph.D. have joined the life science venture capital firm’s Scientific Advisory Board. Comprised of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance to the venture firm as it identifies and invests in promising biopharmaceutical […]
Clinical-stage, rare endocrine disease Company expands leadership team and advances lead candidate for congenital adrenal hyperplasia San Francisco – October 12, 2017 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today provided a corporate update, building upon a previously closed Series A financing of $20 million to expand its […]
CLEVELAND, Ohio – August 28, 2017 – Neuros Medical, Inc., a neuromodulation company, announced today the appointment of Tom Wilder as President and CEO.
Endeavour Vision and RiverVest Venture Partners Lead Funding TOLEDO, Ohio, Aug. 15, 2017 /PRNewswire/ — VentureMed Group®, Inc., (“VMG” or the “Company”) a medical device company developing and commercializing next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), today announced it had raised $15 million in new equity financing. The Series B […]
— Board of Directors appoints Robert Alexander as CEO and Adam Tomasi as COO & CFO — Allakos plans to initiate a broad, multi-indication clinical program with AK002 in 2017 SAN CARLOS, Calif., August 15, 2017 – Allakos Inc., a private, clinical-stage biopharmaceutical company focused on the development of therapeutic antibodies for the treatment of allergic, […]
CLEVELAND, Ohio – August 7, 2017 – Neuros Medical, Inc., a neuromodulation company, announced today that it has closed a $20 million Series AA venture capital financing. U.S. Venture Partners led the financing, and was joined by Boston Scientific, Aperture Venture Partners, Osage University Partners, and JumpStart, Inc.
Funds to support clinical development of APX001, compound with novel mechanism to treat life-threatening fungal infections SAN DIEGO – August 2, 2017 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing
Seattle, WA – May 15, 2017 – Genoa Pharmaceuticals, Inc., a biopharmaceutical company focused on development of improved therapies for idiopathic pulmonary fibrosis (IPF) and other severe pulmonary indications, today announced the completion of a $62 million Series A financing.
Tryton stent is the first dedicated bifurcation device to receive regulatory approval in the U.S. Cordis to be exclusive U.S. distributor of the Tryton stent. DURHAM, N.C.–(BUSINESS WIRE)–March 6, 2017–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced the U.S. Food and Drug Administration (FDA) has approved the […]
SAN DIEGO – January 05, 2017 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced the appointments of Ciara Kennedy, Ph.D. to President and Chief Executive Officer (CEO) and Karen Joy Shaw, Ph.D., to Chief Scientific Officer (CSO). In conjunction with this announcement, the company’s former President and CEO, […]
By: David Nicklaus Source: St. Louis Post-Dispatch Date: December 2, 2016 When RiverVest Venture Partners opened its doors in 2000, hopes were high that it would be an important funding source for St. Louis’ nascent biotechnology industry. RiverVest went on to be a highly successful venture capital firm, managing $290 million and demonstrating a knack […]